Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates

García-Castillo, María; Morosini, Marı́a-Isabel; Gálvez, María; Baquero, Fernando; Campo, Rosa del; Meseguer, María Antonia

doi:10.1093/jac/dkn337

Cited by 61 publications

(52 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…self-replicate, and can form a biofilm 32) . Although the biofilm shows low virulence, these organisms evade the host immune response and increase the resistance to antibiotic treatment.…”

Section: Ureaplasma and Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Bronchopulmonary Dysplasia andUreaplasma: What Do We Know So Far?

Haye

Hütten²,

Kunzmann

et al. 2017

Neonatal Med

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity. BPD is a chronic respiratory disease related to lung-injury during the primary course of critical lung disease such as respiratory distress syndrome or when abnormal development of the preterm lung occurs. Abnormal lung development not only results from primary lung injury in the first days after birth, but also secondary injury through abnormal repair resulting in arrested and abnormal alveolarization, fibrosis and pulmonary vascular dysgenesis. Chorioamnionitis is a risk factor that plays an important role in the development of BPD. Ureaplasma subspecies (spp.) are the most common isolated organisms from chorioamniotic tissue after premature births. Therefore Ureaplasma spp. appear to play an important role in the development of BPD, and treatment or prophylactic treatment of these infections or coloni zation may reduce the incidence, morbidity and mortality of BPD. Ureaplasma spp. infections are challenging not only to treat, but also to diagnosis in a timely manner. This review summarizes the current state of treatment and new developments in the treatment of Ureaplasma exposure in premature infants.

show abstract

“…self-replicate, and can form a biofilm 32) . Although the biofilm shows low virulence, these organisms evade the host immune response and increase the resistance to antibiotic treatment.…”

Section: Ureaplasma and Diagnosismentioning

confidence: 99%

“…Although the biofilm shows low virulence, these organisms evade the host immune response and increase the resistance to antibiotic treatment. The exact mechanism remains unknown but complicates treatment options with antibiotics in general 9,32) and may explain the inconsistent therapy effects.…”

Section: Ureaplasma and Diagnosismentioning

confidence: 99%

Bronchopulmonary Dysplasia andUreaplasma: What Do We Know So Far?

Haye

Hütten²,

Kunzmann

et al. 2017

Neonatal Med

View full text Add to dashboard Cite

show abstract

“…The biofilm is by no means affected by the increase in pH, which may be the result of metabolic events of the amplified bacterial population (Udayalaxmi et al, 2012). A biofilm is an intricate collection of sessile bacterial 13 cells, which is covered by an extracellular matrix of biopolymeric substances (García-Castillo et al, 2008). The pathogenic function of a biofilm is to allow the bacteria to repel the host's immune defenses and tolerate higher concentrations of antimicrobial agents, explaining the recurrence rates of BV (Danielsson et al, 2011).…”

Section: Pathogenesis Of Bacterial Vaginosismentioning

confidence: 99%

Normal flora and bacterial vaginosis in pregnancy: an overview

Redelinghuys

Ehlers

Dreyer

et al. 2015

Critical Reviews in Microbiology

View full text Add to dashboard Cite

The female genital tract is an intricate, yet balanced ecosystem that hosts a variety of different residential microflora. The physiological changes that occur during pregnancy may disrupt this balanced ecosystem and predispose women to a potentially pathogenic microbiota. Bacteria that are associated with bacterial vaginosis (BV) are opportunistic pathogens that frequently form part of this microbiota. The overgrowth of and infections with these bacteria are linked to poor obstetric outcomes and increased transmission of other reproductive tract infections (RTIs). These infections increase women's susceptibility of acquiring HIV, the rates of HIV shedding and the development of Acquired Immune

show abstract

“…Acknowledged pathogens include Escherichia coli, other Enterobacteriaceae, Enterococci (Enterococcus faecalis), Staphylococci (S. aureus and CNS-coagulase negative Staphylococci) and Pseudomonas aeruginosa, but may also include Chlamydia trachomatis and the urogenital Mycoplasmata, Ureaplasma species (U. parvum and U. urealyticum) and Mycoplasma species (M. hominis and M. genitalium) (66). E.coli, Staphylococci and Enterococci may generate bacterial biofilms (67)(68)(69), whereas agents such as Ureaplasma spp., Chlamydia trachomatis and Enterococci may infect prostate cells and act intracellularly.…”

Section: Two Pivotal Macrolide Targets In the Prostate Gland: Intracementioning

confidence: 99%

“…Categories II CBP and III CP/CPPS may be caused by cryptic, difficult-to-grow bacteria such as Chlamydia trachomatis and the urogenital Mycoplasmata. Electron microscopy, new molecular diagnostic methods for the detection of bacterial nucleic acids and immunological methods able to detect, at the infection site, secretory IgAs specific to these micro-organisms, appear to be the diagnostic techniques of choice for detecting difficult-to-diagnose chronic infections (68,69).…”

Section: Two Pivotal Macrolide Targets In the Prostate Gland: Intracementioning

confidence: 99%

Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)

et al. 2011

View full text Add to dashboard Cite

Abstract. Chronic bacterial prostatitis (CBP) is a persistent infection of the prostate characterized by poor quality of life mainly due to frequent relapse episodes caused by incomplete eradication of causative pathogens. Aggressive antibacterial therapy is required to attenuate the severe symptoms of CBP and to achieve a permanent cure. Although fluoroquinolones are currently recommended as first-choice agents, macrolide antibiotics are emerging as a noteworthy option for the treatment of CBP. Macrolide antibiotics are characteri zed by an impressive array of distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties. These properties include high intracellular accumulation in phagocytes and at sites of infection, including the prostate; broad antibiotic but also biofilm-inhibiting properties; immunomodulating and inflammation-resolving activities. These features offer particular advantages for the treatment of chronic infections of the prostate gland, which are not easily amenable to drug therapy. Macrolides may be exploited to counteract the unsatisfactory rates of clinical symptom improvement and pathogen eradication. The results of a number of clinical trials support this proposal.

show abstract

Differences in biofilm development and antibiotic susceptibility among clinical Ureaplasma urealyticum and Ureaplasma parvum isolates

Cited by 61 publications

References 9 publications

Bronchopulmonary Dysplasia andUreaplasma: What Do We Know So Far?

Bronchopulmonary Dysplasia andUreaplasma: What Do We Know So Far?

Normal flora and bacterial vaginosis in pregnancy: an overview

Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)

Contact Info

Product

Resources

About